Abuse of prescription opioids continues to be a serious public health concern, with as many as 12.5 million individuals aged 12 or older reporting nonmedical use of prescription pain relievers in 2015. Oxycodone ARIR is the first abuse-deterrent formulation of an IR opioid approved by the Food and Drug Administration and was developed to have similar relative bioavailability to IR oxycodone. Patients can be converted from IR oxycodone to the same dose and dosing regimen of Oxycodone ARIR. It has been demonstrated that when crushed and taken intranasally, Oxycodone ARIR has a 47% and a 23% reduction in mean maximum drug liking compared with crushed intranasal IR oxycodone and intact oral Oxycodone ARIR, respectively.
Explore related content and topics
Poster
A Retrospective Analysis of the Effects of Protocol Design on Completion Rates in Outpatient Clinical Trials in Subjects with Schizophrenia or Schizoaffective Disorder
Subject attrition from randomized Schizophrenia trials is a significant problem and has been found in a meta-analysis to be as high as 76%. The…
Case Study
Collaboration in Neonatal Study Addresses and Resolves Multi-Stage Difficulties
PRA’s project team turned around a challenging neonatal seizure study to enable successful recruitment. The relationships between the sponsor and the…
Blog
In the News: Innovative Methods on the Horizon for Diagnosing Alzheimer’s
A recent study shows that a blood test can detect Alzheimer’s disease early in its progression. It’s as accurate as other more invasive, expensive…